Alexander Light, Nikhil Mayor, Emma Cullen, Alex Kirkham, Anwar R Padhani, Manit Arya, Joyce G R Bomers, Tim Dudderidge, Behfar Ehdaie, Alex Freeman, Stephanie Guillaumier, Richard Hindley, Amish Lakhani, Douglas Pendse, Shonit Punwani, Ardeshir R Rastinehad, Olivier Rouvière, Rafael Sanchez-Salas, Ivo G Schoots, Heminder K Sokhi, Henry Tam, Clare M Tempany, Massimo Valerio, Sadhna Verma, Geert Villeirs, Jan van der Meulen, Hashim U Ahmed, Taimur T Shah
BACKGROUND AND OBJECTIVE: Magnetic resonance imaging (MRI) can detect recurrences after focal therapy for prostate cancer but there is no robust guidance regarding its use. Our objective was to produce consensus recommendations on MRI acquisition, interpretation, and reporting after focal therapy. METHODS: A systematic review was performed in July 2022 to develop consensus statements. A two-round consensus exercise was then performed, with a consensus meeting in January 2023, during which 329 statements were scored by 23 panellists from Europe and North America spanning urology, radiology, and pathology with experience across eight focal therapy modalities...
March 21, 2024: European Urology